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ABSTRACT 
In this study, a multiple-unit gastroretentive sustain release drug delivery system of Olopatadine hydrochloride was developed from a 
completely aqueous environment, avoiding the use of any organic solvent, thus releasing the drug for a prolonged duration of time. Emulsion 
gelation technique was used to prepare beads. The beads with edible oil were prepare by mixing and homogenizing olive oil and water 
containing pectin and molten wax which was then extruded in to calcium chloride solution. The effects of carnauba wax on drug entrapment 
efficiency, floating lag time and morphology and drug release was studied. It was found that carnauba wax was sufficient to sustain the drug 
release at gastric pH. The results show that these beads can entrap drug in sufficient amount and also can successfully deliver the drug in 
stomach for a prolong duration of time avoiding the use of any organic solvent.  
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INTRODUCTION 
Oral route of administration is one of the oldest and most 
extensively used routes for the administration of drug 
providing convenient method of effectively achieving both 
local and systemic effect. Various approaches are made in 
designing the formulations, which will overcome the 
disadvantages of conventional dosage forms, which include 
sustained/controlled release drug delivery system.1 Multiple-
unit floating systems may be an attractive option since they 
have been shown to lesser inter- and intra- subject 
availabilities in drug absorption as well as to lower the 
chances of dose dumping.2 different approaches of floating 
drug delivery system like air compartment multi-unit 
system, hollow microspheres (microballoons) prepared by 
the emulsion solvent diffusion method,3 microparticles based 
on low density foam powder, beads prepared by emulsion 
gelatin method etc. can be distributed widely throughout the 
GIT, providing the possibility  of a longer lasting and more 
reliable release of drugs. The floating wax beads were 
prepared by the emulsion gelation method. The formation of 
beads occurs by the cross-linking of the calcium ions with 
pectin to form calcium pectinate. The morphology, floating 
properties, swelling studies, drug content, drug entrapment 
efficiency and drug release study was carried out. The 
purpose of the present study was to investigate the effect of 
incorporated wax, which prepared by the emulsion gelation 
method on the drug release profile. 
MATERIALS AND METHODS 
Materials 
Olopatadne hydrochloride was received as generous gift 
from Aurobindo Pharma LTD. Research Center (A Division of 
Aurobindo Pharma), Hyderabad. Pectin, Olive oil, Carnauba 
wax, Calcium chloride used were of laboratory grade and 
available at institute. 
Preparation of floating wax beads  
The emulsion of pectin, olive oil and Olopatdine  
hydrochloride was prepared in distilled water using a high 
speed homogenizer (IKA T25) at 3000 rpm. The weighed 
amount of the wax was melted on the water bath at the 
temperature of more than 50C of melting point of the wax. 
The molten wax was dispersed in the previously heated 
homogenized emulsion of pectin, olive oil and Olopatadine 
hydrochloride and mixed until the homogeneous mixture 
was obtained. The hot melted mixture was extruded in the 
2% w/v Calcium chloride solution through 22G syringe. The 
beads formed were allowed to remain in the calcium chloride 
solution for 10 – 20 mins for the hardening of the beads. The 
beads formed were then filtered and washed thoroughly 
with water to remove the excess of calcium from the surface 
of the beads.4 
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Composition of formulation 
Table 1: Composition of formulation: 
Formulation 
Code 
Drug Pectin Olive oil Carnauba wax Water Q.S. 
 
(mg) (gm) (ml) (gm) (ml) 
F1 500 4 30 1 100 
F2 500 4 30 4 100 
F3 500 4 30 12 100 
F4 500 4 30 16 100 
 
Micromeritic properties 
All the prepared formulations of floating beads were 
evaluated for bulk density, tapped density, Carr's index and 
Hausner's ratio.5,6 
Percentage yield 
All the prepared formulations of floating beads were 
evaluated for the percentage yield by using following 
formula.5,7 
                                        
                                Mass of formulation 
Bulk Density =     
                              Total volume of formulation  
                                      
                                      Weight of the powder  
Tapped Density  =     
                                    Tapped volume of powder 
 
              Tapped Density 
Hausners ratio =           
                                  Bulk Density 
                                                     Tapped density − Bulk density 
Carr’s compressibility index =                                                      ×100 
                                                               Tapped density 
 
Determination of drug content and drug entrapment 
efficiency 
50 mg of beads were weighed and crushed in a pastel 
mortar and the crushed material was dissolved in 25 ml of 
0.1 N Hydrochloric acid. The solution was kept for 24 hrs. 
Volume of this solution was made up to 50 ml with 
washings of mortar. Then it was filtered. The filtrate was 
assayed by spectrophotometically using a UV 
spectrophotometer (Schimadzu, UV, 1800). The drug 
content and the entraptment efficiency were determined.8 
Floating lag time and floating time 
The formulated bead sample (n=20) were placed in a 
beaker filled with 0.1N HCl (pH 1.2) solution. Temperature 
was maintained at 37 0C. The floating time of beads were 
observed for 12 hrs. The preparation was thought of to 
possess buoyancy in the test solution only when all the 
beads floated in it. The time the formulation took emerge on 
the surface of the medium (floating lag time) and the time 
for which the formulation remains floating on the surface of 
the medium (floating time) were noted.9  
Swelling studies 
Beads were studied for swelling characteristics. Only those 
batches were selected which have good drug content and 
entrapment efficiency more than 50%. Sample from drug 
loaded beads were taken, weighed and placed in wire 
basket of USP dissolution apparatus I. The basket 
containing beads put in a beaker containing 100 ml of 0.1N 
HCl (pH 1.2) maintained at 37 0C. The beads were 
periodically removed at predetermined intervals and 
weighed. Then swelling ratio was calculated as per the 
following formula.10  
                                    Ws − Wo 
Swelling index =                                × 100 
                                          Wo 
Where, Ws = weight of swollen beads, 
 Wo = weight of dried beads 
Particle size determination 
The particle size of beads was determined by the dry state 
using optical microscopy method. The stage micrometer 
and eyepiece micrometer were used for the measurement 
of the particle size. The size of the beads present in the 1cm3 
area of the slide was counted.11 
Surface characterization 
Surface characterization of beads were examined with a 
scanning Electron Microscopy (Diya labs, airoli, Mumbai) 
beads were mounted on metal grids using double-sided 
tape and coated with gold under vaccum.12 
Differential Scanning Calorimetry (DSC) 
The DSC measurements were performed on a DSC 60, 
Shimadzu, Japan differential scanning calorimeter with 
thermal analyzer. All accurately weighed samples were 
placed in a sealed aluminium pans, before heating under 
nitrogen flow (10 ml/min) at a scanning rate of 100C per 
min from 25 to 3000C. An empty aluminium  pan was used 
as reference.13 
Fourier Transform Infrared Spectroscopy (FTIR) 
The compatibility study was carried out by using Fourier 
transform infrared spectrophotometer (BRUKER). FTIR 
study was carried on pure drug and physical mixture of 
drug and polymer. Physical mixtures were prepared and 
samples were kept for 1 month at room temperature. 
Infrared absorption spectrum of Olopatadine hydrochloride 
was recorded over the wave number 4000 to 400 cm-1 using 
Fourier Transform spectrophotometer. 13, 14 
In- vitro drug release study 
The release of Olopatadine hydrochloride from sustained 
release floating wax bead was determined using USP 
dissolution apparatus I at 50 rpm. The dissolution medium 
used 900ml of 0.1N HCl (pH1.2) and temperature was 
maintained at 37 0C. A sample (5ml) was withdrawn from 
the dissolution apparatus at 0 min., 1hr, 2hr, 4hr, 6hr, 8hr, 
10hr, 12hr. The samples were filtered through Whatman 
filter paper and analysed using UV method. Cumulative % 
drug release was calculated and observed. The dissolution 
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of the formulation was compared with the 250mg of the 
capsule containing 5mg of the drug.4  
Best fit kinetic model for optimized formulation 
The data obtained from study of diffusion kinetics of the 
optimized formulation was studied to obtain the best fit 
model. The best fitted model is the one which gives the 
highest R2 value and least slope value. 
Stability study 
Stability study of the formulation which gave maximum 
dissolution rate was carried out to point out any visual 
physical or chemical change made in the formulation after 
storing it at elevated temperature and humidity conditions. 
The optimized formulation was store in ambient colour 
bottle and stored at 400 C ± 20C and 75% ± 5% Relative 
humidity for three months. Floating wax beads was 
analysed for the drug content.15 
Statistical Analysis 
Results of ex-vivo experiments are reported as SEM 
analysis. The classical zero order release curve was found to 
be linear. The curves plotted according to Higuchi model 
were also found to be linear. The drug release occurs 
probably by diffusion and erosion and dissolution. From the 
above tables it was seen that the best fit model for 
formulation was Zero order kinetic, such type of model was 
applicable when sustained release dissolution mechanism 
are seen. 
RESULTS AND DISCUSSION 
Micromeritics properties 
From the study of the micromeritics properties of the 
formulation it was found that the bulk density of the 
formulation lied within range of 0.3604 – 0.4804 g/cm3, 
tapped density within range of 0.5563- 0.4569. The Carr’s 
index lies within range of 6.76 – 11.70 and Hausner’s ratio 
within range of 1.2658 – 1.1277 which indicates that the 
prepared formulation have good flow property (Table 2).
 
Table 2: Micromeritics properties of the formulation 
Batch 
Code 
Bulk density 
(gm/ml) ± SD 
Tapped density 
(gm/ml) ± SD 
Carr’s index       ± 
SD 
Hausner’s ratio ± SD 
F1 0.4804 ± 0.0045 0.5563 ± 0.0049 6.76 ± 0.0357 1.1277 ± 0.0010 
F2 0.3920 ± 0.0013 0.4693 ± 0.0021 11.70 ± 0.0578 1.1904 ± 0.0085 
F3 0.4312 ± 0.0020 0.5182 ± 0.0016 9.22 ± 0.0441 1.1834 ± 0.0058 
F4 0.3604 ± 0.0011 0.4569 ± 0.0025 8.10 ± 0.0482 1.2658 ± 0.0011 
                                                                                                                         (n=3) 
 
Percentage yield 
All formulations F1 – F4 found percentage yield 97.14 – 
95.20% which lied in the normal range in (Table 3). 
Table 3: Percentage yield of the formulations 
Sr. No. Batch Code Percentage Yield (%) 
1 F1 97.14 
2 F2 96.84 
3 F3 95.65 
4 F4 95.20 
 
Drug content and drug entrapment efficiency 
The percentage drug content of all prepared formulations 
was found to be in the range of 92.56 – 98.77%. Therefore 
uniformity of drug content was maintained in all 
formulations (Table 2). The percentage drug entrapment 
efficiency of all prepared formulations was found to be in 
the range of 90.28% - 92.62%. Therefore entrapment 
efficiency was found to be less due to the diffusion of the 
drug into the calcium chloride solution during the 
formation of the microspheres (Table 4). 
Table 4: Drug content of the formulation 
Sr. No. Batch Code Contents(%) ± SD 
1 F1 96.87 ± 0.2743 
2 F2 96.84 ± 0.8369 
3 F3 96.22 ± 0.7968 
4 F4 95.21 ± 0.5750 
(n=3) 
Floating lag time and floating time 
Floating lag time in the range of 1.21 – 1.76 min. and 
floating time >12hr for all formulations F1-F4. This is due 
the increase in the concentration of the carnauba wax. 
(Table 5). 
 
Table 5: Floating lag time and floating time of formulations 
Sr. No.  Batch Floating lag time (min.) Floating time ( hrs.) 
1 F1 1.76 ±  0.04630 > 12 
2 F2 1.35 ±  0.09391 > 11 
3 F3 1.21 ±  0.00707 > 12 
4 F4 1.25 ±  0.04221 > 12 
 (n=3)  
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Swelling studies 
For all prepared batches (F1-F4), percent swelling ratio was 
found to be in the range of 10 – 20.66 %. The F1 batch 
showed the maximum swelling index. This is because of the 
lipophillic nature of the carnauba wax which affected the 
swelling of the beads. (Table 6). 
Table 6: Swelling Index of formulations 
Sr. No. Batch Code Swelling ± SD 
1 F1 20.66 ± 0.02471 
2 F2 15.3  ± 0.05241 
3 F3 14.66 ± 0.0254 
4 F4 10  ±  0.01679 
   (n=3) 
Particle size determination 
For F1-F4 batches average particle size was found to be in 
the range of 1.21 – 1.52 mm (Table 7). 
Table7: Particle size determination of formulation 
Sr. No. Batch Code Particle size (mm) ± SD 
1 F1 1.51 ± 0.0251 
2 F2 2.00 ± 0.0163 
3 F3 1.46 ± 0.0258 
4 F4 1.27 ± 0.0355 
                                                                                                        (n=3) 
 
Surface characterization 
The SEM result showed that the particle size of formulation 
was found to have regular and spherical shape with rough 
and uneven surface (Figure 1). 
 
Figure No. 1: Surface morphology of the formulation 
Differential scanning calorimetric studies 
Olopatadine Hydrochloride was compatible with polymer. 
There is slightly peak broadening in physical mixture of 
polymer to pure Olopatadine  Hydrochloride (Figure 2). 
Fourier transform infrared spectroscopy FTIR spectrum of 
the physical mixture shows that there is no interaction 
between drug and polymer (Figure 3). 
 
 
Figure No. 2: DSC thermogram of Olopatadine hydrochloride 
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Figure No.3: DSC thermogram of formulation 
 
In vitro drug release 
The In vitro drug release study of different formulation 
maximum drug release 96.65% was shown by F1 batch. The 
data also suggested that floating beads formulation were 
capable to produce linear drug release for longer period of 
time. Drug release profile of formulation F1 to F4 shown in 
(Figure No. 4) and dissolution profile F1 to F4 signified 
sustained drug release. Out of four formulations maximum 
release after 12 hr was found for F1 formulation. (Table 8  
and figure 4)  
 
Table 8: In-vitro drug release of different batches of the formulation 
Time (hr) F1 F2 F3 F4 
0 0 0 0 0 
1 11.04 ± 0.030 9.39 ± 0.025 6.73 ± 0.015 6.36 ± 0.020 
2 19.81 ± 0.050 20.36 ± 0.088 10.49 ± 0.040 11.81 ± 0.020 
4 36.55 ± 0.086 45.03 ± 0.030 19.26 ± 0.020 22.58 ± 0.030 
6 58.52 ± 0.020 55.06 ± 0.051 23.10 ± 0.023 28.86 ± 0.030 
8 71.71 ± 0.025 74.04 ± 0.061 31.36 ± 0.026 42.57 ± 0.010 
10 86.16 ± 0.040 91.65 ± 0.047 34.06 ± 0.021 44.22 ± 0.030 
12 96.65 ± 0.050 95.5 ± 0.015 58.74 ± 0.040 45.04 ± 0.020 
                                                                                                                               (n=3) 
 
Figure No.4: Drug release profile of formulations F1-F4 
 
From the comparative study of the formulation with capsule 
containing the dose of 5 mg of Olopatadine hydrochloride, it 
was found that the capsule containing drug showed the 
98.51% drug release within 60 mins. and marketed 
formulation showed the 98.50% drug release within 50 
min. while the prepared formulation (F1 Batch) showed 
maximum drug release up to 96.65 % within 12 hrs. (Table 
9 and figure 5 (A),(B)) 
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Comparative dissolution profile of the formulation with marketed formulation  
Table 9: Comparative dissolution profile of the formulation with marketed  formulation 
 
 
 
Figure No. 5(A): Comparative dissolution profile of 
formulation with capsule filled with drug. 
 
Figure No. 5(B): Comparative dissolution profile 
of formulation with marketed formulation.
 
Kinetic model for F1 batch 
In order to investigate the mode of release from floating 
beads data were analysed with following mathematical 
model. 
A. Zero order kinetic 
B. First order kinetic 
C. Higuchi equation 
D. Korsemeyer-peppas equation 
The classical zero order release curve was found to be linear. 
The curves plotted according Higuchi model were also found 
to be linear. Korsemeyer-Peppas release curves R2 was found 
to be ≥ 0.965 for all 4 formulations. The drug release occurs 
probably by diffusion and erosion and dissolution. After 
comparing the coefficient of regression (r2) values of 
different kinetic models, drug release kinetics for optimized 
floating beads best fitted in Zero order kinetic release 
followed by Higuchi such type of model was applicable when 
sustained release dissolution mechanism are seen (Table 10 
& Figure 6: (A), (B), (C) and (D) ).  
Drug release by using different models by F1 batch
 
Table 10: Drug release by using different models by F1 batch 
Batch Kinetic Model 
F1 Zero 
Order 
First 
Order 
Higuchi Model Korsemeyer-peppas 
R2 R2 R2 R2 
0.991 0.893 0.991 0.986 
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TIME % CDR 
(MIN) CAP(PLANE DRUG) CAP(FORMULATION) MKT. FORMULATION 
0 0 0 0 
10 36.80 1.17 39.54 
20 47.77 3.36 61.48 
30 61.45 4.19 72.45 
40 80.68 6.38 86.16 
50 98.37 8.02 98.50 
60 98.51 11.04 
 
120 
 
19.81 
 
240 
 
36.56 
 
360 
 
58.58 
 
480 
 
71.72 
 
600 
 
86.16 
 
720 
 
96.65 
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A. Zero order kinetic 
 
Figure No. 6(A): Zero order kinetic study 
B. First order 
 
Figure No. 6(B): First order kinetic study 
C. Higuchi equation 
 
Figure No. 6(C): Higuchi plot 
D. Korsemeyer-peppas equation 
 
Figure No. 6 (D): Korsemeyer- peppas plot
 
Stability study 
The sample were withdrawn after 1, 2 and 3 months and 
subjected to following tests a shown in. The accelerated 
stability studies (carried for 3 months), at temperature of 
40 C 0 ± 2 C and % RH 75% ± 5% RH indicated that the 
developed 0 floating pectinate microspheres were 
unaffected after 03 months storage under accelerated 
condition as no change was observed in the appearance and 
colour of the formulation. On the basis of these results, it 
may be concluded that the F1 formulation developed is 
stable under accelerated condition of 03 months (Table 11).
 
Table 11: Details of stability study for F1 batch 
Test Before After 
  
0 month 1 month 2 month 3 month 
Drug release  96.65 ± 0.246% 96.61 ± 0.236% 93.58 ± 0.254 92.55 ± 0.251 
Floating lag time >12 hrs >12hrs >12hrs >12hrs 
 
CONCLUSION 
From the above study it may be concluded the use of 
hydrophobic carriers like waxes can be done for achieving 
the sustain release action. The low density materials like oils 
were used to attend the floating of the formulation. The 
study also suggested that the floating wax microspheres can 
be implemented as a suitable drug carrier for sustaining the 
release of the drugs with short biological half life. 
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